Fang‐Shu Ou
About
Fang‐Shu Ou is a scholar working on Oncology, Pathology and Forensic Medicine and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Fang‐Shu Ou has authored 146 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 34 papers in Pathology and Forensic Medicine and 31 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Fang‐Shu Ou's work include Colorectal Cancer Treatments and Studies (43 papers), Acute Myocardial Infarction Research (25 papers) and Genetic factors in colorectal cancer (23 papers). Fang‐Shu Ou is often cited by papers focused on Colorectal Cancer Treatments and Studies (43 papers), Acute Myocardial Infarction Research (25 papers) and Genetic factors in colorectal cancer (23 papers). Fang‐Shu Ou collaborates with scholars based in United States, United Kingdom and France. Fang‐Shu Ou's co-authors include Matthew T. Roe, Eric D. Peterson, John S. Rumsfeld, Tracy Y. Wang, Eric D. Peterson, Sunil V. Rao, W. Brian Gibler, Ralph G. Brindis, Heinz‐Josef Lenz and Donna Niedzwiecki and has published in prestigious journals such as JAMA, Circulation and Nature Communications.
In The Last Decade
Fang‐Shu Ou
134 papers receiving 4.3k citations
Peers
Fang‐Shu Ou
Erluo Chen United States
Eva Culakova United States
Helen Guo Canada
Fergal J. Fleming United States
Natalia Udaltsova United States
David J. Bentrem United States
David M. Charytan United States
Georgina Buck United Kingdom
Sandra C. Bryant United States
Soo‐Mee Bang South Korea
Citations per year, relative to Fang‐Shu Ou Fang‐Shu Ou (= 1×)
peers
Erluo Chen
Countries citing papers authored by Fang‐Shu Ou
Since
Specialization
Citations
This map shows the geographic impact of Fang‐Shu Ou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fang‐Shu Ou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fang‐Shu Ou more than expected).
Fields of papers citing papers by Fang‐Shu Ou
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Fang‐Shu Ou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fang‐Shu Ou. The network helps show where Fang‐Shu Ou may publish in the future.
Co-authorship network of co-authors of Fang‐Shu Ou
This figure shows the co-authorship network connecting the top 25 collaborators of Fang‐Shu Ou. A scholar is included among the top collaborators of Fang‐Shu Ou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fang‐Shu Ou. Fang‐Shu Ou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pai, Rish K., Mitesh J. Borad, Hao Xie, et al.. (2025). Immune Checkpoint Inhibitors for Mismatch Repair–Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic. JCO Precision Oncology. 9(9). e2500492–e2500492.
2.
Pai, Reetesh K., Kenneth Lee, Catherine E. Hagen, et al.. (2025). Quantitative Analysis of Rectal Cancer Biopsies With the Digital Pathology Segmentation Algorithm QuantCRC Associates With Therapy Response and Recurrence. Laboratory Investigation. 105(8). 104187–104187.
3.
Cheng, En, Fang‐Shu Ou, Alan P. Venook, et al.. (2024). Plant-based diet and survival among patients with metastatic colorectal cancer. JNCI Journal of the National Cancer Institute. 117(1). 169–179.
4.
Kusne, Yael, Terra L. Lasho, Christy M. Finke, et al.. (2024). Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study. JCO Precision Oncology. 8(8). e2400143–e2400143.
5.
Gile, Jennifer, Hani M. Babiker, Rondell P. Graham, et al.. (2024). Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. The Oncologist. 30(8).
6.
Innocenti, Federico, Xueping Qu, Fang‐Shu Ou, et al.. (2023). DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. Journal of Clinical Oncology. 42(4). 399–409.
7.
Johnson, Radia Marie, Xueping Qu, Ling‐Yuh Huw, et al.. (2022). ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nature Communications. 13(1). 5478–5478.
8.
Raghav, Kanwal, Fang‐Shu Ou, Alan P. Venook, et al.. (2022). Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). Journal of Clinical Oncology. 41(3). 472–478.
9.
Lee, Seohyuk, Sui Zhang, Fang‐Shu Ou, et al.. (2022). Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). The Oncologist. 27(6). e494–e505.
10.
Casulo, Carla, Jesse G. Dixon, Fang‐Shu Ou, et al.. (2021). Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances. 5(6). 1737–1745.
11.
Gile, Jennifer, Fang‐Shu Ou, Amit Mahipal, et al.. (2021). FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology. 5(5). 1228–1240.
12.
Jatoi, Aminah, Fang‐Shu Ou, Daniel H. Ahn, et al.. (2021). Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. The Oncologist. 26(7). 610–618.
13.
Innocenti, Federico, Alexander B. Sibley, Amy S. Etheridge, et al.. (2020). Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clinical Cancer Research. 27(1). 267–275.
14.
Guercio, Brendan J., Sui Zhang, Alan P. Venook, et al.. (2020). Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum. 4(3). pkaa024–pkaa024.
15.
Ou, Fang‐Shu, Jennifer Le‐Rademacher, Karla V. Ballman, Alex A. Adjei, & Sumithra J. Mandrekar. (2020). Guidelines for Statistical Reporting in Medical Journals. Journal of Thoracic Oncology. 15(11). 1722–1726.
16.
Yuan, Chen, Kaori Sato, Bruce W. Hollis, et al.. (2019). Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clinical Cancer Research. 25(24). 7497–7505.
17.
Wei, Alice C., Fang‐Shu Ou, Qian Shi, et al.. (2019). Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Annals of Surgical Oncology. 26(13). 4489–4497.
18.
Martin, Seth S., Fang‐Shu Ou, L. Kristin Newby, et al.. (2013). Patient- and Trial-Specific Barriers to Participation in Cardiovascular Randomized Clinical Trials. Journal of the American College of Cardiology. 61(7). 762–769.
19.
Melloni, Chiara, Fang‐Shu Ou, Kenneth E. Schmader, et al.. (2009). Age and Persistent Use of Cardiovascular Medication After Acute Coronary Syndrome: Results from Medication Applied and Sustained Over Time. Journal of the American Geriatrics Society. 57(11). 1990–1996.
20.
Kutcher, Michael A., Lloyd W. Klein, Fang‐Shu Ou, et al.. (2009). Percutaneous Coronary Interventions in Facilities Without Cardiac Surgery On Site: A Report From the National Cardiovascular Data Registry (NCDR). Journal of the American College of Cardiology. 54(1). 16–24.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Erluo Chen Breakdown of academic impact, for papers by Eva Culakova Breakdown of academic impact, for papers by Helen Guo Breakdown of academic impact, for papers by Fergal J. Fleming Breakdown of academic impact, for papers by Natalia Udaltsova Breakdown of academic impact, for papers by David J. Bentrem Breakdown of academic impact, for papers by David M. Charytan Breakdown of academic impact, for papers by Georgina Buck Breakdown of academic impact, for papers by Sandra C. Bryant Breakdown of academic impact, for papers by Soo‐Mee Bang